Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) have been assigned a consensus rating of “Buy” from the eleven ratings firms that are presently covering the company, MarketBeat reports. Eleven investment analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $69.56.
Several analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $65.00 target price on shares of Jasper Therapeutics in a research report on Wednesday, May 15th. Evercore ISI assumed coverage on shares of Jasper Therapeutics in a research report on Wednesday, April 3rd. They issued an “outperform” rating and a $65.00 price objective on the stock. Stifel Nicolaus assumed coverage on shares of Jasper Therapeutics in a research report on Thursday, June 27th. They issued a “buy” rating and a $86.00 price objective on the stock. TD Cowen assumed coverage on shares of Jasper Therapeutics in a research report on Monday, March 18th. They issued an “outperform” rating on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a research report on Tuesday, June 18th.
View Our Latest Research Report on Jasper Therapeutics
Institutional Investors Weigh In On Jasper Therapeutics
Jasper Therapeutics Stock Down 4.7 %
Shares of JSPR stock opened at $19.10 on Wednesday. The stock has a market cap of $287.65 million, a P/E ratio of -3.39 and a beta of 2.21. Jasper Therapeutics has a 52 week low of $4.00 and a 52 week high of $31.01. The company’s fifty day simple moving average is $22.85 and its two-hundred day simple moving average is $20.66.
Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last announced its earnings results on Tuesday, May 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.23. On average, analysts anticipate that Jasper Therapeutics will post -4.41 EPS for the current fiscal year.
Jasper Therapeutics Company Profile
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
See Also
- Five stocks we like better than Jasper Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Top 3 Defense Stocks That Should Be on Your Radar
- How Investors Can Find the Best Cheap Dividend Stocks
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- MarketBeat Week in Review – 7/8 – 7/12
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.